Get the Stockscreener App
1.55
7.64%
0.11
After Hours:
1.58
0.03
+1.94%
Beyondspring Inc stock is traded at $1.55, with a volume of 15,122.
It is up +7.64% in the last 24 hours and down -9.36% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
See More
Previous Close:
$1.44
Open:
$1.58
24h Volume:
15,122
Relative Volume:
0.80
Market Cap:
$63.74M
Revenue:
$1.88M
Net Income/Loss:
$-16.06M
P/E Ratio:
-7.8362
EPS:
-0.1978
Net Cash Flow:
$-50.09M
1W Performance:
+5.44%
1M Performance:
-9.36%
6M Performance:
-19.27%
1Y Performance:
-27.23%
1-Day Range:
$1.49
$1.615
1-Week Range:
$1.37
$1.66
52-Week Range:
$1.21
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.55 | 59.21M | 1.88M | -16.06M | -50.09M | -0.1978 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
BeyondSpring (BYSI) to Release Quarterly Earnings on Tuesday - MarketBeat
BeyondSpring (NASDAQ:BYSI) Stock Price Passes Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Sahm
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.1%Here's Why - MarketBeat
BYSI (BeyondSpring Inc. Ordinary Shares) posts narrower than expected Q4 2021 loss, shares rise nearly 3 percent on positive market reception.Beat Estimates - Cổng thông tin điện tử Tỉnh Sơn La
BeyondSpring : Corporate Presentation - marketscreener.com
BeyondSpring reports preclinical data on plinabulin-ADC combos - Investing.com
BeyondSpring reports preclinical data on plinabulin-ADC combos By Investing.com - Investing.com South Africa
BeyondSpring presents preclinical data on Plinabulin ADC combinations - StreetInsider
Cancer-drug combo cut animal deaths and extended survival in AACR study - Stock Titan
Recap Report: Whats the RSI of BeyondSpring Inc stock2026 Fed Impact & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Is BeyondSpring Inc exposed to political risk2026 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Quarterly Earnings: Can BeyondSpring Inc maintain sales growth2026 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
BeyondSpring Reports 2025 Year-End Financial Results - ADVFN
Are investors bullish on BeyondSpring (BYSI) Stock | Price at $1.82, Up 2.77%Crowd Risk Alerts - Newser
What is the long-term potential of BeyondSpring (BYSI) Stock | Price at $1.82, Up 3.58%Profit Surge - Newser
BeyondSpring (BYSI) director awarded 23,902 stock options at $1.64 strike price - Stock Titan
Pullback Watch: Can BeyondSpring Inc beat the S P 500Weekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - Yahoo Finance
Is BeyondSpring (BYSI) Stock Undervalued Now | Price at $1.75, Up 2.34%Investment Signal Network - Newser
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why - Defense World
BYSI PE Ratio & Valuation, Is BYSI Overvalued - Intellectia AI
BeyondSpring Stock Crosses 50-Day Moving Average - National Today
BeyondSpring (NASDAQ:BYSI) Stock Crosses Above 50 Day Moving AverageShould You Sell? - MarketBeat
BeyondSpring (BYSI) director receives 22,165 stock options grant - Stock Titan
Director Delaney granted BYSI stock options under 2017 plan - Stock Titan
BeyondSpring (BYSI) director receives 21,730 options at $1.64 strike - Stock Titan
BeyondSpring (BYSI) awards CSO 17,840 stock options at $1.64 strike - Stock Titan
BeyondSpring (BYSI) CEO Huang Lan receives grant of 11,514 stock options - Stock Titan
BeyondSpring (BYSI) director Xu Sihai awarded 18,689 stock options at $1.64 - Stock Titan
BYSI Uptrend Accelerates on CEO - Newser
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 - Bitget
BeyondSpring (NASDAQ:BYSI) Trading Down 0.6%Should You Sell? - MarketBeat
Layoff Watch: Can BeyondSpring Inc beat the S P 5002026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin - marketscreener.com
BeyondSpring Inc. 2025 Annual Report – Plinabulin Clinical Progress, SEED TPD Platform, and Strategic Collaborations with Eli Lilly & Eisai - Minichart
EV Market: How does BeyondSpring Inc perform in inflationary periodsWeekly Trade Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
BeyondSpring Inc. (BYSI) Reports FY2025 Earnings - AlphaStreet
BeyondSpring Files 2025 Annual Report on Form 10-K - Bitget
BeyondSpring 10-K: $0M Revenue, $(0.02) EPS, net loss $(14.22)M - TradingView
BeyondSpring (NASDAQ: BYSI) posts 2025 loss and warns it needs more funding - Stock Titan
BYSI: Net loss narrowed to $14.2M in 2025 as Plinabulin advanced in global NSCLC trials - TradingView — Track All Markets
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BeyondSpring Inc. Confirms Phase 3 Overall Survival Benefit for Plinabulin in NSCLC and Plans DUBLIN-4 Study - quiverquant.com
Jobs Data: How does BeyondSpring Inc compare to its peersTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
BeyondSpring (NASDAQ: BYSI) narrows 2025 loss as Plinabulin Phase 3 data drive new trial - Stock Titan
Wall Street Recap: Whats the RSI of BeyondSpring Inc stockPortfolio Return Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
BeyondSpring (BYSI) Stock Analysis Report | Financials & Insights - Benzinga España
Buyback Watch: Will BeyondSpring Inc stock go up in YEAR2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):